Overview

Inflammatory Pathogenesis of Coronary Atherosclerosis in HIV

Status:
Completed
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
The investigators are studying whether an anti-inflammatory intervention improves impaired coronary endothelial function (CEF) in HIV+ people with no clinical coronary artery disease (CAD).
Phase:
Phase 2
Details
Lead Sponsor:
Johns Hopkins University
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Colchicine